Cargando…
An empirically generated responder definition for rosacea treatment
OBJECTIVE: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea. METHODS: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or compara...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598547/ https://www.ncbi.nlm.nih.gov/pubmed/28932125 http://dx.doi.org/10.2147/CCID.S139352 |
_version_ | 1783263928462082048 |
---|---|
author | Staedtler, Gerald Shakery, Kaweh Endrikat, Jan Nkulikiyinka, Richard Gerlinger, Christoph |
author_facet | Staedtler, Gerald Shakery, Kaweh Endrikat, Jan Nkulikiyinka, Richard Gerlinger, Christoph |
author_sort | Staedtler, Gerald |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea. METHODS: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or comparator treatments. The severity of rosacea was described by the Investigator Global Assessment (IGA) and the number of lesions. Patients with the IGA score of “clear/minimal” were considered as responders, and those staying in the range of IGA “mild to severe” as nonresponders. The respective number of lesions was determined. RESULTS: A total of 2,748 patients providing 12,410 measurements were included. After treatment, responders showed 2.23±2.48 lesions (median 2 lesions [0–3]), and nonresponders showed 13.74±10.40 lesions (median 12 lesions [6–18]). The optimal cutoff point between both groups was 5.69 lesions. CONCLUSION: The calculated cutoff point of 5.69 lesions allows discrimination of responders (5 or less remaining lesions) and nonresponders (6 or more remaining lesions) of therapeutic interventions in rosacea. |
format | Online Article Text |
id | pubmed-5598547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55985472017-09-20 An empirically generated responder definition for rosacea treatment Staedtler, Gerald Shakery, Kaweh Endrikat, Jan Nkulikiyinka, Richard Gerlinger, Christoph Clin Cosmet Investig Dermatol Original Research OBJECTIVE: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea. METHODS: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or comparator treatments. The severity of rosacea was described by the Investigator Global Assessment (IGA) and the number of lesions. Patients with the IGA score of “clear/minimal” were considered as responders, and those staying in the range of IGA “mild to severe” as nonresponders. The respective number of lesions was determined. RESULTS: A total of 2,748 patients providing 12,410 measurements were included. After treatment, responders showed 2.23±2.48 lesions (median 2 lesions [0–3]), and nonresponders showed 13.74±10.40 lesions (median 12 lesions [6–18]). The optimal cutoff point between both groups was 5.69 lesions. CONCLUSION: The calculated cutoff point of 5.69 lesions allows discrimination of responders (5 or less remaining lesions) and nonresponders (6 or more remaining lesions) of therapeutic interventions in rosacea. Dove Medical Press 2017-09-08 /pmc/articles/PMC5598547/ /pubmed/28932125 http://dx.doi.org/10.2147/CCID.S139352 Text en © 2017 Staedtler et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Staedtler, Gerald Shakery, Kaweh Endrikat, Jan Nkulikiyinka, Richard Gerlinger, Christoph An empirically generated responder definition for rosacea treatment |
title | An empirically generated responder definition for rosacea treatment |
title_full | An empirically generated responder definition for rosacea treatment |
title_fullStr | An empirically generated responder definition for rosacea treatment |
title_full_unstemmed | An empirically generated responder definition for rosacea treatment |
title_short | An empirically generated responder definition for rosacea treatment |
title_sort | empirically generated responder definition for rosacea treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598547/ https://www.ncbi.nlm.nih.gov/pubmed/28932125 http://dx.doi.org/10.2147/CCID.S139352 |
work_keys_str_mv | AT staedtlergerald anempiricallygeneratedresponderdefinitionforrosaceatreatment AT shakerykaweh anempiricallygeneratedresponderdefinitionforrosaceatreatment AT endrikatjan anempiricallygeneratedresponderdefinitionforrosaceatreatment AT nkulikiyinkarichard anempiricallygeneratedresponderdefinitionforrosaceatreatment AT gerlingerchristoph anempiricallygeneratedresponderdefinitionforrosaceatreatment AT staedtlergerald empiricallygeneratedresponderdefinitionforrosaceatreatment AT shakerykaweh empiricallygeneratedresponderdefinitionforrosaceatreatment AT endrikatjan empiricallygeneratedresponderdefinitionforrosaceatreatment AT nkulikiyinkarichard empiricallygeneratedresponderdefinitionforrosaceatreatment AT gerlingerchristoph empiricallygeneratedresponderdefinitionforrosaceatreatment |